How can we balance the risk of recurrent venous thromboembolism following an episode of unprovoked VTE and the increased bleeding risk associated with continued anticoagulation?
What should be the anticoagulation treatment in a patient receiving long-term vitamin K antagonists or novel oral anticoagulants in whom an interventional procedure is planned? Is it necessary to discontinue the anticoagulants, or is it safe to perform the procedures while the patient is on therapeutic doses of the anticoagulant?
What is your opinion on using bridging therapy in patients with a history of deep vein thrombosis?
What are the 2017 recommendations on the use of bridging therapy – should it be routinely used or not?
What is the currently recommended duration of dual antiplatelet treatment in patients after coronary artery stenting, carotid artery stenting, or peripheral artery stenting?
In your opinion, are there any new trial results, drugs, or procedures in the field of thromboembolic disease that are worth particular attention?
How long would you treat a 19-year-old woman in whom acute proximal venous thromboembolism occurred as early as one month after starting oral contraception? Would you perform diagnostic workup for thrombophilia in this patient?
In which patients with atrial fibrillation and coronary stenting should we consider continuing treatment with an oral anticoagulant plus an antiplatelet agent (aspirin or clopidogrel) after the 12-month mark following the procedure?
In your opinion, are there any new trial results, drugs, or procedures in the field of thromboembolic disease that are worth particular attention?
Many patients with a history of pulmonary embolism ask about discontinuation of anticoagulant treatment. What would be your advice in such cases? What precautions would you recommend?
English
Polski
Español
українська